who's who

3 Houston innovators to know this week

This week's Houston innovators to know roundup includes Aimee Woodall of The Black Sheep Agency, Alok Pant of Unvired, and Abbey Donnell of Work & Mother. Photos courtesy

Houston's rising COVID-19 case numbers and Texas' new regulations for bars and restaurants are a sure sign that the city isn't out of the woods from the pandemic — and that includes Houston's startups and entrepreneurs.

This week's three Houston innovators to know include three people who are advocating for continuing through the pandemic — the right way, from using tech to better communicate with employees at home to factoring in the new moms when you roll out your back-to-work plans.

Aimee Woodall, CEO and founder of the Black Sheep Agency

Aimee Woodall has been focused on innovation and creativity during COVID-19 for her own company, The Black Sheep Agency, but also for its clients. Photo courtesy of The Black Sheep Agency

Aimee Woodall founded The Black Sheep Agency in order to help impact-based businesses tell their stories. Now, amid COVID-19, that mission is more important than ever.

"We write, we design, we build campaigns, we work in the digital space — whatever it takes to tell the story of the organization and to rally other people to not only pay attention to what the organization is doing but to also find their own way to participate in moving that mission forward," Woodall shares on this week's episode of the Houston Innovators Podcast.

Thinking back to when COVID-19 really started affecting business and her campaigns, Woodall remembers how she and her team had to reevaluate existing content, pivot planned projects, and, in some cases, cancel events or programming. Read more.

Alok Pant, founder and CEO of Unvired

A Houston software startup has created a communication tool and is allowing free access amid the COVID-19 pandemic. Photo courtesy of Unvired

A Houston startup recently released an app to help employees voice their concerns and keep businesses with their finger on the pulse of employee morale. The survey is customizable for each business and contains questions with the most important factors such as employee health and well being, communication, confidence, and leadership.

"Digital Forms fits in with a whole new paradigm in the software world," says Alok Pant, CEO of Unvired. "It allows a business user to make their own specialized applications fast and easy with no coding necessary."

The low-code platform has a drag-and-drop form building feature to instantly deploy surveys, can store data in the Unvired Cloud, and instantly generate reports for insights in the administration portal. Read more.

Abbey Donnell, founder of Work & Mother

Abbey Donnell's startup, Work & Mother, provides a new way for new moms to pump breast milk during the workday. Courtesy of Work & Mother

As offices started to reopen and release new safety measures that will be put in place in the office, Abbey Donnell noticed a certain group or people who were going to be affected by these measures: New moms. Mother's rooms are usually multi purposeful, lack access to sinks, and seen as expendable, Donnell writes in a guest column for InnovationMap,

"If mother's needs are not part of this vital return to work safety conversation, women may be left behind," she writes. "So let's start the conversation." Read more.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted